Characterisation of tumor microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact. An OCTIPS Consortium study.

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
British Journal of Cancer

Publisher Rights Statement:
This is a pre-copyedited, author-produced version of an article accepted for publication in British Journal of Cancer following peer review. The version of record "Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinicopathological impact (an OCTIPS Consortium study)" is available online at:doi.org/10.1038/s41416-018-0157-z.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Characterisation of tumor microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact. An OCTIPS Consortium study.

Running title: Microvessel density evolution in ovarian cancer.

Ilary RUSCIT01,2, Dan CACSI0RE CASTILLO-TONG3, Ignace VERGOTE4, Iulia IGNA0T1, Mandy STANSKES5, Adrian VANDERSTICHELE4, Jacek GLAJZER1, Hagen KULBE1, Fabian TRILLSCH6,7, Alexander MUSTEA8, Caroline KREUZINGER3, Pierluigi BENEDETTI PANICI9, Charlie GOURLEY10, Hani GABRA11,12, Marianna NUTI2, Eliane T. TAUBE5, Mirjana KESSLER13, Jalid SEHOUL1, Silvia DAR0B-ESFAHANI5, Elena Ioana BRAICU1*. 

2. Cell Therapy Unit and Laboratory of Tumor Immunology, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
3. Translational Gynecology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
4. Division of Gynaecological Oncology, Leuven Cancer Institute, Department of Gynaecology and Obstetrics, University Hospital Leuven, Catholic University of Leuven, Herestraat 49, B-3000 Leuven, Belgium, European Union.
5. Institute of Pathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin Germany.
6. Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistrasse 15, Munich, Germany;
7. Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Martinistr. 46, Hamburg, Germany.
8. Department of Gynecology and Obstetrics, University Medicine of Greifswald, Greifswald, Germany.
9. Department of Gynecology, Obstetrics and Urology, Sapienza University of Rome, Rome, Italy.
10. Nicola Murray Centre for Ovarian Cancer Research, University of Edinburgh Cancer Research UK Centre, MRC IGMM, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK.
11. Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
12. Clinical Discovery Unit, AstraZeneca, Cambridge, UK
13. Department of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany.

* These authors contributed equally to this work.

#Corresponding Author: Ilary Ruscito, MD

Department of Gynecology, European Competence Center for Ovarian Cancer, Campus Virchow Klinikum, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany
Phone. +49 (0) 30 450 564 476; Fax. +49 (0) 30 450 564 939
E-mail address: ilary.ruscito@uniroma1.it

ABSTRACT
Background: High-grade serous ovarian cancer (HGSOC) intratumoral vasculature evolution remains unknown. The study investigated changes in tumor microvessel density (MVD) in a large cohort of paired primary and recurrent HGSOC tissue samples and its impact on patients’ clinico-pathological outcome.

Methods: 222 primary (pOC) and recurrent (rOC) intra-patient paired HGSOC were assessed for immunohistochemical expression of angiogenesis-associated biomarkers (CD31, to evaluate MVD, and VEGF-A). Expression profiles were compared between pOCs and rOCs and correlated with patients’ data.

Results: High intratumoral MVD and VEGF-A expression were observed in 75.7%(84/111) and 20.7%(23/111) pOCs, respectively. MVD\textsuperscript{high} and VEGF\textsuperscript{(+)} samples were detected in 51.4%(57/111) and 20.7%(23/111) rOCs, respectively. MVD\textsuperscript{high}/VEGF\textsuperscript{(+)} co-expression was found in 19.8%(22/111) and 8.1%(9/111) of pOCs and rOCs, respectively (p=0.02). Pairwise analysis showed no significant change in MVD (p=0.935) and VEGF-A (p=0.121) levels from pOCs to rOCs. MVD\textsuperscript{high} pOCs were associated with higher CD3\textsuperscript{(+)} (p=0.029) and CD8\textsuperscript{(+)} (p=0.013) intratumoral effector TILs, while VEGF\textsuperscript{(+)} samples were most frequently encountered among BRCA-mutated tumors (p=0.019). Multivariate analysis showed VEGF and MVD were not independent prognostic factors for OS.

Conclusion: HGSOC intratumoral vasculature did not undergo significant changes during disease progression. High concentration of CD31\textsuperscript{(+)} vessels seems to promote recruitment of effector TILs. The study also provides preliminary evidence of the correlation between VEGF-positivity and BRCA status.

Key Words: ovarian cancer; HGSOC; CD31; microvessel density; MVD; VEGF; BRCA; angiogenesis; bevacizumab; survival.
BACKGROUND

High-grade serous ovarian carcinoma (HGSOC) still accounts for the highest mortality rate among all ovarian cancer (OC) histotypes, with almost 80% of all new deaths from OC being caused by this distinct subgroup of ovarian tumors [1-4]. International groups of opinion leaders have recognized the designing of new translational studies on recurrent and end-stage HGS tumor tissue samples as a key “unmet need” in the understanding of HGSOC biology and clonal evolution [4].

In this scenario, analysis of the evolution process affecting intratumoral vasculature during HGSOC progression is a pivotal issue to be still elucidated. After decades of paralysis in primary OC first-line chemotherapy treatment, indeed, incorporation of bevacizumab in the upfront regimen for advanced newly diagnosed disease [5] has changed the “standard of care paradigm” of advanced primary OC, although characterized by less survival impact than expected [6,7,8]. Thus, understanding changes in the vasculature or identification of prognostic biomarkers of response to vasculature targeting is needed. Unfortunately, there are currently no predictive biomarkers to tailor bevacizumab treatment in OC patients.

A full knowledge of molecular changes involving intratumoral vasculature from primary to recurrent HGSOC is still lacking and may provide new opportunities to: 1) tailor treatment with currently available anti-angiogenetic agents, 2) shed light on acquired resistance mechanisms, 3) develop new targeted therapies.

Aim of this study was to identify changes occurring from primary to recurrent HGSOC in tumor tissue expression of the angiogenesis-associated biomarkers CD31, applied for detecting microvessels density (MVD) [9-11], and VEGF-
A[12], by analyzing a large cohort of paired primary and recurrent HGSOC tissue samples. Secondary endpoints included the correlation of biomarkers expression with patients’ clinico-pathological characteristics and survival data.

MATERIALS AND METHODS

Sample Collection

Paired cancer tissue samples belonging to HGSOC patients were collected during primary and secondary cytoreduction. Patients were treated with primary debulking surgery followed by platinum-based chemotherapy between 1985 and 2013 and were retrospectively and consecutively selected from OCTIPS (Ovarian Cancer Therapy–Innovative Models Prolong Survival, Agreement No.279113-2) Consortium database. Included patients underwent both primary (pOC) and recurrent (rOC) surgery in one of the European Gynecologic Oncology referral Centers of the following Institutions: Charité Universitätsmedizin Berlin, Germany; Catholic University of Leuven, Belgium; Imperial College, London, UK; University of Edinburgh, UK; University Medical Center Hamburg-Eppendorf, Germany.

Inclusion criteria were: availability of paired primary and recurrent cancer tissue samples from HGSOC patient together with clinical annotation. Exclusion criterion was: neoadjuvant chemotherapy treatment, due to the need to analyze primary chemo-naïve tumors. Approval from each local ethics committee was obtained (EK207/2003, ML2524, 05/Q0406/178, EK130113, 06/S1101/16). All included samples underwent central histopathological assessment to confirm HGSOC histology and ensure tumor tissue content and quality.

Immunohistochemistry
Tissue microarrays (TMA) were constructed for immunohistochemical staining.

Each primary and recurrent tumor tissue sample was represented within the TMA by two tumor cores, each containing at least 90% of cancer cells.

Sections from TMA were deparaffinized in xylol, rehydrated in graded alcohol and boiled in pressure cooker for 5 minutes in citrate buffer (pH=6), for CD31 staining, or in EDTA (pH=9), for VEGF staining. Rabbit anti-human CD31 antibody (clone ab32457; Abcam, Cambridge, MA, USA) and rabbit anti-human VEGF-A antibody (clone A-20; Santa Cruz Biotechnology, Dallas, TX, USA) were diluted 1:20 and 1:250, respectively, and incubated on slides for 60 minutes at room temperature. Bound antibodies were visualized using DAKO Real Detection System and DAB+ (3,3′-diaminobenzidine; DAKO, Glostrup, Denmark) as a chromogen. Finally, slides were co-stained with hematoxylin.

CD31 stained samples were assessed in terms of MVD. MVD was determined by averaging the number of vessels from three distinct areas of tumor with highest vessels density examined at 200x magnification [13-15].

Samples were further classified into “MVD\textsuperscript{high}” (≥16.3 vessels) or “MVD\textsuperscript{low}” (<16.3 vessels), establishing the cut-off level of MVD count for dichotomization at first quartile (primary samples), being the value able to maximize difference in OS hazard ratio [Table S1][13,15,16].

For VEGF staining evaluation, the number of stained tumor cells within the whole TMA cores (0%=0; 1-10%=1; 11-50%=2; >50%=3) was multiplied with the intensity of staining (negative=0; weak=1; moderate=2; strong=3)[17], resulting in a semiquantitative immunoreactivity score (IRS) ranging from 0 to 9.
Samples were classified as “VEGF(+)”, for VEGF-high tumor expression (IRS=4-9), or as “VEGF(-)”, for absent/weak focal staining (IRS=0-3). As positive control for IHC were used human liver sections. Samples staining was assessed independently by two co-authors (IR and SDE).

**Patients’ clinico-pathological data**

Patients’ clinico-pathological data, including somatic BRCA status from 52 included patients, were retrieved from OCTIPS Consortium database [18]. GCIG criteria were applied to define platinum-resistance and platinum-sensitivity[19]. RECIST Criteria were applied during patients’ follow-up to define HGSOC relapse. No residual tumor was defined intraoperatively by the surgeon in case no macroscopic tumor could be detected at the end of cytoreduction.

In order to investigate any association between different tumor vasculature profiles and intratumoral immune infiltrate in both pOCs and rOCs, MVD and/or VEGF profiles were matched with previous OCTIPS data on tumor infiltrating lymphocytes (TILs), assessed through the immunohistochemical expression of CD3, CD4 and CD8 biomarkers, as previously reported [21]. Furthermore, immunosuppressive TILs were evaluated through the expression of T regulatory cells-specific biomarker FoxP3, using the mouse anti-human FOXP3 antibody (clone ab20034; Abcam, Cambridge, MA, USA, 1:200, 1.5 h at room temperature). The count of stained FoxP3-positive TILs was then performed automatically with the VM Scope Quantifier, as previously reported [21].

**Statistical Analysis**

Statistical analysis was performed using SPSS version 22.0 (SPSS Inc, Chicago, IL, USA). Difference in biomarker expression between pOCs and rOCs was assessed through the correlation test (Spearman coefficient, 2-
tailed) and “Wilcoxon signed rank” non-parametric test for related samples. Fisher’s exact test was applied to correlate MVD and/or VEGF tumor expression with patients’ clinico-pathological categorical data. Patients’ progression-free interval (PFI), progression-free survival (PFS) and overall survival (OS) were identified through Kaplan–Meier analysis (Log-Rank test). PFI was defined as the time interval from the last adjuvant chemotherapy to relapse, whereas progression-free survival (PFS) was established as the time interval between first recurrence diagnosis and tumor progression. Univariate and multivariate survival analyses were performed applying Cox-regression model. Multivariable models were obtained among variables reporting a p-value ≤0.1 in univariate analysis. P values ≤0.05 were evaluated statistically significant.

RESULTS

222 intra-patient paired primary and recurrent HGSOC tissue samples derived from 111 patients were included. Patients’ characteristics are listed in Table 1. To note, only 2/111 (1.8%) patients received bevacizumab in front-line chemotherapy, thus the staining of recurrent samples have not been influenced by first-line administration of anti-angiogenetic compounds.

MVD staining
MVD$^{\text{high}}$ staining was detected in 75.7% (84/111) of pOC and in 51.4% (57/111) of rOC, whereas MVD$^{\text{low}}$ staining was found in 24.3% (27/111) and in 48.6%
(54/111) of pOC and rOC, respectively. MVD\textsuperscript{low} staining was twice as prevalent in relapsed tumours compared to primary disease (p=0.0003, Fisher's exact test, Fig.1a-d). Nevertheless, globally, pair-wise analysis revealed no tendency towards a change in MVD to higher or lower levels in recurrent samples (p=0.935, Wilcoxon test; Fig.1e), as well as no significant correlation between pOCs and rOCs in MVD was reported (Spearman correlation, p=0.920; Spearman coefficient: 0.01).

**VEGF-A expression**

VEGF IRS distribution in both pOCs and rOCs is shown in Fig.2a,2d. The same percentage of VEGF\textsuperscript{+} (20.7%, 23/111) and VEGF\textsuperscript{-} (79.3%, 88/111) tumor samples was found between pOCs and rOCs, respectively, (p=1, Fisher’s exact test, Fig.2b,c,e,f), although no significant correlation between pOCs and rOCs VEGF IRS values could be observed (p=0.505, Spearman coefficient 0.06). Furthermore, pairwise analysis confirmed no tendency towards a change in VEGF IRS levels at tumor relapse (p=0.121, Wilcoxon test; Fig.2g).

**MVD\textsuperscript{high} and VEGF\textsuperscript{+} co-expression in pOCs versus rOCs.**

MVD\textsuperscript{high} and VEGF\textsuperscript{+} co-expression was more frequent in pOCs group (22/111, 19.8%) compared to rOCs (9/111, 8.1%) (p=0.02, Fisher’s exact test, Fig.S1).

**Relationship between MVD and/or VEGF-A expression with TILs.**

Results showed that MVD\textsuperscript{high} levels in pOCs samples were associated with higher CD3\textsuperscript{+} (p=0.029, Mann-Whitney test) and CD8\textsuperscript{+} (p=0.013) effector TILs, but not with a higher FoxP3\textsuperscript{+} (p=0.443) T-regulatory cells infiltrate. To note,
the correlation between MVD and CD3(+)/CD8(+) TILs disappeared at tumor recurrence. No significance between pOCs or rOCs VEGF expression or MVD_{high}+VEGF(+) co-staining with TILs was reported (Fig.S2, Table S2).

MVD and/or VEGF-A profiles and patients’ clinico-pathological factors.

Analysis on the correlation between MVD and/or VEGF expression in pOCs with patients’ clinico-pathological characteristics is shown in Table 2. In particular, VEGF(+) primary HGSOCs and MVD_{high}/VEGF(+) primary samples were most frequently encountered among somatic-BRCA mutated tumors compared to somatic-BRCA wild type cases (p=0.019, Fisher’s exact test). No further significant associations between different intratumoral vasculature profiles and patients’ age at diagnosis, FIGO stage, residual tumor after primary debulking or first-line platinum response was identified.

Decrease of VEGF expression in rOCs was observed only in BRCA-mutated patients (p=0.053, Wilcoxon test), although this association did not reach statistical significance (Fig.S3).

Survival

Patients, whose pOCs resulted MVD_{high}, VEGF(+) or co-stained for both biomarkers, were found to have a significantly improved OS compared to patients without these intratumoral profiles at primary disease (Fig.3g-i). In particular, median OS for MVD_{high} and MVD_{low} patients was 67 and 46 months respectively (p=0.019), median OS for VEGF(+) and VEGF(−) patients resulted 76 versus 52 months, respectively (p=0.036), while median OS for patients with
co-stained pOCs was 76 months, compared to 52 months in women without co-expression (p=0.021).

On the contrary, no influence of pOCs or rOCs MVD and/or VEGF expression on patients’ time to progression after primary (PFI) or first recurrent disease (PFS) was reported (Fig.3a-f).

Multivariate analysis for OS and PFI was carried out on the whole patients’ population (n=111) and also on the subgroup of patients (n=52) with known tumor somatic-BRCA status. Table 3a,b shows that VEGF-A was not found to be an independent prognostic factor for OS anymore when considering also somatic BRCA mutational status. Only somatic BRCA mutation (HR:0.354, CI 95%:0.133-0.994; p=0.038), high CD4(+) TILs (HR:0.997, CI 95%:0.995-1.000; p=0.038) and first-line platinum response (HR:0.216, CI 95%:0.051-0.991; p=0.037) were found to independently improve HGSOC patients’ OS.

When analyzing the PFI in patients with or without BRCA somatic mutations, advanced FIGO stage (HR:18.261, CI 95%:1.28-260.17; p=0.032) and low CD4(+) TILs (HR:0.996, CI 95%:0.993-0.998; p=0.001) were the only independent poor prognostic factors (Table 3c,d).

**DISCUSSION**

In the last decade, “omics” sciences provided fundamental insight into the understanding of HGSOC biology [3], showing as one distinct malignancy with its own characteristic phenotype, etiology and progression profile [22]. Although known for its aggressive behavior, HGSOC has a higher change to show
durable response after first-line chemotherapy, compared to other OC histologies [23], as well as its common platinum-sensitivity allows it to access a more varied panel of experimental second-line combinations [24].

Unfortunately, progression from HGSOC is often rapid and chemo-resistance develops [4].

In this context, understanding the biological changes occurring to HGSOC during disease progression is an essential issue through which new identified biomolecular signatures, marking the HGSOC clinical evolution, could help developing new tailored treatment strategies.

In this study, OCTIPS Consortium aimed to identify modifications involving HGSOC intratumoral vasculature from primary to recurrent disease, by assessing the evolution of cancer MVD and VEGF-A expression. Results showed that: 1) MVD and/or VEGF levels did not undergo significant changes from pOC to rOC (being in line with already available clinical findings, as bevacizumab is showing mild improvement in PFS, in both primary and relapsed situation)[5,7,8]; 2) High MVD levels in pOC seems to sustain the intratumoral recruitment of effector TILs and were associated with better OS in HGSOC patients; 3) VEGF(+) HGSOCs were most frequently encountered among somatic BRCA-mutated tumors and VEGF-positivity correlates with better OS in this HGSOC cohort; 4) MVD and VEGF were not independent prognostic factor for OS when taking into account the BRCA mutational status and TILs profile.

The definition of “intratumoral microvessel density” has been coined in the middle of 90’s to objectivize the entity of blood supply available within the tumor mass to sustain cancer growth[25]. Intratumoral vessels are usually
characterized by impaired vascular maturation, poor functionality and defects in endothelial architecture. Immaturity of the new generated tumor-associated vasculature results in excessive permeability, poor perfusion and imperfect blood flow[26].

During the last 20 years, different studies recognized “high” MVD a poor prognostic factor for cancer patients[27-29], including women affected by OC[30]. Different biomarkers have been adopted to assess MVD in OC, including Von Willebrand Factor, CD105, CD34 and CD31, being CD34 the most used MVD detector and the biomarker associated with the poorest HR for OS (HR:1.67, C.I.95%:1.36-2.35) compared to other MVD detectors (HR:1.32, C.I.95%:0.82-1.82)[30].

CD31, also known as “platelet endothelial cell adhesion molecule-1” (PECAM-1) is a transmembrane glycoprotein expressed on endothelial cells, platelets, neutrophils and T-cells. It is a key factor to maintain the integrity of endothelial cells permeability barrier and to promote the controlled activation of T-cells and their survival[11,31,32], thus being expression of a normalized endothelium able to sustain the correct trafficking of T-cells into the tumor. In line with CD31 biological role, we observed that MVD\textsuperscript{high} levels in pOCs samples correlated with higher CD3\textsuperscript{(+)} and CD8\textsuperscript{(+)} TILs, but not with a higher FoxP3\textsuperscript{(+)} T-lymphocytes infiltrate, thus suggesting that a high concentration of intratumoral CD31\textsuperscript{(+)} vessels might be able to promote the intratumoral recruitment of effector T-cell populations, thus ultimately improving patients’ survival[33].

Recently, Bais et al.[16] identified CD31-dependent MVD as a predictive biomarker for bevacizumab response in first-line treated OC patients. This finding might be consequence of intratumoral endothelial maturity, represented
by high CD31-dependent MVD levels, able to ensure a normalized blood flow, which is pivotal for intratumoral drug delivery and efficacy[26].

Vascular Endothelial Growth Factor (VEGF) is a key angiogenetic cytokine that regulates cell mitosis and endothelial cells permeability[34]. Overexpression of VEGF has been found to correlate with cancer relapse and decreased survival in patients affected by different solid tumors, including OC[35]. Despite previous studies, absence of significant changes in MVD and VEGF profile following disease progression of this unique cohort, indicates that these markers are not major drivers of molecular cancer evolution in vivo, but rather remain supportive factors.

One of the most intriguing outcomes of our study is that VEGF-A overexpression in pOC has been most frequently found among patients with a cancer somatic mutation of BRCA1/2 genes. This finding is in line with two other previously published papers. In 2013, Danza[36] observed that BRCA-mutated breast cancer patients reported higher levels of VEGF mRNA (P=0.04) compared with those without BRCA mutations. In 2016, another study revealed that a VEGF-dependent gene signature (VDGs) was overexpressed in OC BRCA mutation carriers [37]. An interesting hypothesis explaining the linking between BRCA1 mutation and VEGF overexpression in HGSOC has been recently proposed: in 2015 Desai A and Colleagues [38] pointed out that wild-type BRCA1 binds to Ubc9, which induces Caveolin-1 expression, down-regulates VEGF and regulates endothelial function in normal ovaries and fallopian tubes. In HGSOC with BRCA1 dysfunction, Ubc9 is not binded and this inhibits Caveolin-1 expression causing increased VEGF levels, loss of endothelial function and accumulation of ascites. Compared to these previous
studies, we also confirmed in our cohort the positive influence of BRCA mutations on OC patients’ survival [39,40], as well as the significant association between BRCA mutation and VEGF positivity determined VEGF positivity a good prognostic factor in our HGSOC series. This result may also reflect the highly selection of the sample analyzed, which only included HGSOC patients, who can also undergo secondary cytoreductive surgery for recurrence. These patients have usually good performance status and low tumor burden, so there is a selection of patients with a better clinical outcome[41]. Furthermore, patients have been treated in high volume centers, with high experience in surgical treatment of ovarian cancer. Most Centers have been also approved and allowed to participate in the LION (ClinicalTrials.gov Identifier: NCT00712218), DESKTOP III (ClinicalTrials.gov Identifier: NCT01166737) and TRUST (ClinicalTrials.gov Identifier: NCT02828618) studies, based on the high quality of the tumor debulking. Nevertheless, further studies aiming to assess the association between BRCA mutation and VEGF overexpression would provide new instrument to personalize treatment with anti-angiogenetic agents among BRCA-mutated and BRCA wild-type OC patients [42]. In this scenario, the randomized phase III clinical trial ENGOT-ov25/PAOLA-1 (ClinicalTrials.gov Identifier: NCT02477644), which combines in advanced OC patients bevacizumab-based first-line treatment with or without the PARP-Inhibitor olaparib, could be able to add evidence concerning functional impact of VEGF expression in tumors with impaired homologous DNA repair mechanism. To our knowledge, this is the first study analyzing the changes occurring in intratumoral vasculature during disease progression in the largest cohort of
paired primary and recurrent HGSOC samples. It firstly demonstrated that the vascular architecture within the tumor mass, in absence of anti-angiogenic agents administration, is maintained relatively stable during the natural course of the disease. Furthermore, the subanalysis on patients with known somatic BRCA status increases the value of findings by taking into account the impact of BRCA status on patients’ survival[39,40] and provides preliminary evidence of the correlation between VEGF-positivity and BRCA mutation.

The main limitation of the study is its retrospective nature. One of the strengths of this analysis is the large sample size of paired primary and recurrent tumor tissue samples belonging to the same cancer subtype (n=222), the high quality of specimens and the systematization of multicentric patients’ clinico-pathological data. Furthermore, inclusion of patients not subjected to the bevacizumab-based first-line chemotherapy, increase the reliability of the results in comparing intratumoral vasculature profiles from primary to recurrent disease.

Future study on a larger population with known BRCA status, who has been subjected to bevacizumab-based first-line chemotherapy, is warranted to clarify the role of MVD and VEGF in predicting bevacizumab response in both BRCA-wt and BRCA-mutated HGSOC patients.

**ADDITIONAL INFORMATION**

**Ethics approval and consent to participate**

Included patients were previously treated in one of the European Gynecologic Oncology referral Centers of the following Institutions: Charité...
University of Edinburgh, UK; University Medical Center Hamburg-Eppendorf, Germany. Patients had previously signed written informed consent regarding tumor tissue sampling and the collection of their clinico-pathological data for translational research purposes.

Approval from each local ethics committee was obtained (EK207/2003, ML2524, 05/Q0406/178, EK130113, 06/S1101/16). The study was performed in accordance with the Declaration of Helsinki.

**Consent for publication**

Included patients had previously signed written informed consent regarding the anonymous publication of their clinico-pathological data for translational research purposes.

**Availability of data and materials**

Data supporting the results reported are stored in the OCTIPS Consortium database. The documentation of clinical and patient's data was managed with "AlcedisTRIAL the web based documentation system" of Alcedis GmbH, Winchesterstr. 3, 35394 Giessen, Germany.

**Conflict of interest**

The authors declare no conflict of interest.

**Funding**
European Community’s Seventh Framework Program supported this study under the grant agreement No. 279113-2 (OCTIPS).

BMBF supported this study under the Transcan project TH4Respons, grant No.: JTC 2014-121.

**Authors’ contribution**

- Study concepts and design: IR and EIB
- Data acquisition: IR, HK, FT, AV, MS, II
- Quality control of data acquired: DCCT, IV, CG, HG, AM, JS, SDE
- Data analysis and interpretation: IR, SDE, MK, CK, PBP, MN, JG
- Statistical analysis: IR, MS, SDE, ETT
- Manuscript writing: IR and EIB
- Manuscript editing: all coauthors.

**Acknowledgements.**

This work was supported by European Community’s Seventh Framework Program under grant agreement No. 279113-2 (OCTIPS) and by BMBF under the Transcan project TH4Respons, grant No.: JTC 2014-121.

The documentation of clinical and patient's data was managed with “AlcedisTRIAL the web based documentation system” of Alcedis GmbH, Winchesterstr. 3, 35394 Giessen, Germany.

Elena Ioana Braicu, MD, PhD is participant in the BIH Charité Clinician Scientist Program funded by the Charité Universitätsmedizin Berlin and the Berlin Institute of Health.
REFERENCES


**LEGEND TO FIGURES AND TABLES**

**Figure 1.** CD31 immunohistochemistry staining for intratumoral MVD assessment: MVD\(^{\text{high}}\) (a) and MVD\(^{\text{low}}\) (b) pOC samples; MVD\(^{\text{high}}\) (c) and MVD\(^{\text{low}}\) (d) rOC samples. 400x magnification; MVD count among primary and recurrent tumours (box plot – e – and scatter plot – f).

**Figure 2.** VEGF-A immunohistochemistry staining. VEGF-A IRS distribution in primary (a) and recurrent (d) tumor samples. pOCs, VEGF\(^{(+)}\) (b) and VEGF\(^{(-)}\) (c); rOCs, VEGF\(^{(+)}\) (e) and VEGF\(^{(-)}\) (f); VEGF-A IRS among primary and recurrent tumours (box plot – g – and scatter plot – h).

**Figure 3.** MVD and/or VEGF status and progression free survival after primary (PFI, a,b,c) and recurrent (PFS, d,e,f) disease. g-i: MVD and/or VEGF status at primary disease and overall survival. “x-axis”: months; “y-axis”: survival probability.

**Figure S1 (supplementary):** MVD\(^{\text{high}}\) and VEGF\(^{(+)}\) co-staining frequency among pOCs versus rOCs (bar plot). Asterisk indicates significance (p=0.02) between pOCs and rOCs.

**Figure S2 (supplementary):** CD3, CD4, CD8 and FoxP3 staining of intratumoral T lymphocytes.

**Figure S3 (supplementary):** VEGF-A IRS changes from pOCs to rOCs among BRCA-wt (a - box plot – and c – scatter plot; Wilcoxon test: p=0.126; Spearman correlation test: p=0.290; Spearman coefficient -0.200) versus BRCA-mut patients (b – box plot – and d – scatter plot; Wilcoxon test: p=0.053; Spearman correlation test: p=0.226; Spearman coefficient 0.276).

**Table 1.** Patients’ characteristics

**Table 2.** Association of MVD and/or VEGF expression with patients’ clinicopathological characteristics (pOCs).
Table 3. multivariate analysis for OS carried out on a) the whole patients' population (n=111), b) only somatic BRCA-tested population (n=52) and multivariate analysis for PFI carried out on c) the whole patients' population (n=111), d) only somatic BRCA-tested population (n=52).

Table S1 (supplementary): Overall survival (OS) by CD31 MVD quartile.

Table S2 (Supplementary): Correlation between MVD and/or VEGF expression profile in pOC and Tumor Infiltrating Lymphocyte (TILs) phenotype.